Selin Aractingi

Title: Selin Aractingi: Innovator in Pharmaceutical Compositions

Introduction

Selin Aractingi is a notable inventor based in Paris, France. He has made significant contributions to the field of pharmaceuticals, particularly in developing compositions aimed at preventing glucocorticoid-induced thinning of the cornea and skin. With a total of 2 patents, his work is recognized for its potential impact on treating inflammatory skin diseases and conditions affecting the eye.

Latest Patents

Aractingi's latest patents focus on pharmaceutical compositions designed to prevent glucocorticoid-induced corneal thinning. The first patent details a method and composition that utilizes a mineralocorticoid receptor antagonist for topical application. This invention aims to prevent or reduce glucocorticoid-induced thinning in subjects requiring treatment. The second patent similarly addresses glucocorticoid-induced skin thinning, emphasizing the use of a topical pharmaceutical composition that combines glucocorticoids with mineralocorticoid receptor antagonists or inhibitors of MR expression.

Career Highlights

Throughout his career, Selin Aractingi has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and Université Paris Descartes. His research and innovations have contributed to advancements in the pharmaceutical industry, particularly in dermatology and ophthalmology.

Collaborations

Aractingi has collaborated with notable colleagues, including Nicolette Farman and Frederic Jaisser. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions in his field.

Conclusion

Selin Aractingi's work in pharmaceutical compositions showcases his dedication to addressing critical health issues related to glucocorticoid-induced conditions. His contributions are paving the way for new treatments that could significantly improve patient outcomes.